EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Persistent atherogenic lipoprotein changes during lorlatinib therapy

Kimitaka Shibue iD, Kei Kunimasa, Akihiro Hamasaki

JCEM Case Reports · 16.10.2026 · 4 (12)

DOI: 10.1210/jcemcr/luag324 ↗

Kurz gefasst

Fallbericht in der Zeitschrift JCEM Case Reports, online erschienen am 22.10.2026. Verfasst von Kimitaka Shibue und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka 530-8480, Japan. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 12 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Lorlatinib, a third-generation anaplastic lymphoma kinase (ALK)/ROS1 tyrosine kinase inhibitor, frequently induces hypercholesterolemia and hypertriglyceridemia, but longitudinal qualitative lipoprotein changes remain incompletely characterized. We describe a 52-year-old woman with ALK-rearranged non–small cell lung cancer who developed persistent dyslipidemia despite lipid-lowering therapy. Before lorlatinib, total cholesterol was 164 mg/dL (SI [International System of Units]: 4.24 mmol/L) (reference range, 148-248 mg/dL [SI: 3.83-6.41 mmol/L]), low-density lipoprotein (LDL) cholesterol was 52 mg/dL (SI: 1.34 mmol/L) (reference range, 65-139 mg/dL [SI: 1.68-3.59 mmol/L]), and triglycerides were 54 mg/dL (SI: 0.61 mmol/L) (reference range, 30-117 mg/dL [SI: 0.34-1.32 mmol/L]). Within 3 weeks after lorlatinib initiation, these increased to 340, 245, and 166 mg/dL, respectively. Longitudinal profiling showed persistent apolipoprotein B (ApoB) elevation, increased oxidized LDL, and a prominent pre-β-lipoprotein fraction. Subclinical hypothyroidism was later detected, and pitavastatin was switched to rosuvastatin. This case highlights the potential value of ApoB and qualitative lipid assessment during prolonged lorlatinib therapy.

Schlagwörter

Stichwörter der Autor:innen

apolipoproteinsdrug-induced dyslipidemiahypertriglyceridemialipoprotein metabolismlorlatinib

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Medical Research Institute KITANO HOSPITAL, PIIF Tazuke-Kofukai, Osaka 530-8480, Japan.
  • Department of Thoracic Oncology, Osaka International Cancer Institute, Osaka 541-8567, Japan.

ORCID-Profile: Kimitaka Shibue

Zitieren

APA

Shibue, K., Kunimasa, K., & Hamasaki, A. (2026). Persistent atherogenic lipoprotein changes during lorlatinib therapy. JCEM Case Reports, 4(12). https://doi.org/10.1210/jcemcr/luag324

Vancouver

Shibue K, Kunimasa K, Hamasaki A. Persistent atherogenic lipoprotein changes during lorlatinib therapy. JCEM Case Reports. 2026;4(12). doi:10.1210/jcemcr/luag324

BibTeX
@article{Shibue2026,
  author = {Shibue, Kimitaka and Kunimasa, Kei and Hamasaki, Akihiro},
  title = {Persistent atherogenic lipoprotein changes during lorlatinib therapy},
  journal = {JCEM Case Reports},
  year = {2026},
  volume = {4},
  number = {12},
  doi = {10.1210/jcemcr/luag324}
}
Kostenlos starten →